HTG Molecular Diagnostics Announces Completion of Public Offering of Common Stock

HTG Molecular Diagnostics (NASDAQ:HTGM) a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares of its common stock at a price to the public of $2.90 per share, including 1,815,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.
As quoted in the press release:

All of the shares in the offering were sold by HTG. The aggregate gross proceeds from the offering are approximately $40.4 million, before deducting the underwriting discounts and commissions and offering expenses.

Leerink Partners LLC and Cantor Fitzgerald & Co. acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC and LifeSci Capital LLC acted as co-managers for the offering.

Click here to read the full press release.